Cécile Pétigny-Lechartier

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.

S. Lheureux, L. Poulain, M. Guercio, 2014, Cancer letters.

First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.

S. Rault, L. Ligat, F. Lopez, 2015, Journal of medicinal chemistry.

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737

L. Poulain, P. Gauduchon, E. Abeilard, 2016, Molecular Cancer Therapeutics.